osimertinib,lazertinib,amivantamab-vmjw
astrazeneca,yuhan corp,janssen,genmab
['chrysalis-2']
#asco22: data fromchrysalis-2 (ami + laz) show promising orr of 33% &amp; dor 9.6 months in osi and platinum chemo pretreated pts. with classical egfr mut. potential new option in egfr tki resistance 
I am physician and researcher passionate about advancing precision oncology and lung cancer treatments. Views are my own.